Global Pharma Medicine Congress Set for Berlin in March
Further details about the 17th International Conference on Pharmaceutical Medicine (ICPM 2014) have been unveiled.
Further details about the 17th International Conference on Pharmaceutical Medicine (ICPM 2014) have been unveiled.
The congress is jointly organized by the International Federation of Associations of Pharmaceutical Physicians & Pharmaceutical Medicine (IFAPP) and the German Society of Pharmaceutical Medicine (Deutsche Gesellschaft für Pharmazeutische Medizin e.V.’ – DGPharMed).
“Drug development aiming for true innovations has become even more challenging in the past decade. The investments needed further increased, hurdles for approval and reimbursement became more demanding. In a globalized environment all economic regions are directly competing for R&D leadership in drug development,” noted the organizers, adding that the Berlin meeting will focus on the major framework conditions in that field.
The motto of the event is “The World Is Our Partner”. Beyond assessment of the status quo, the presentations will provide participants with an outlook on what it will take to stay on top of drug development. Experts will address the key topics relevant for smart development of better drugs, and there will also be exchange and networking with peers to discuss presentations and new topics.
To read the full release click here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
